Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 18/20 | 1.00 |
| ▸ | IMPDH1 | P20839 | 8/20 | 0.82 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1475591 | 0.93 | IMPDH2 (0.87) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1475861 | 0.92 | IMPDH2 (0.85) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474014 | 0.90 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6490216 | 0.90 | IMPDH2 (0.81) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474340 | 0.89 | IMPDH2 (0.80) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6488186 | 0.87 | IMPDH2 (0.81) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474188 | 0.87 | IMPDH2 (0.85) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1473286 | 0.87 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474040 | 0.86 | IMPDH2 (0.83) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6495844 | 0.86 | IMPDH2 (0.83) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1127054-A4 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2006-11-02 | — | — | EP | claimed |
| US-20040102497-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H (US) | 2004-05-27 | — | — | US | claimed |
| US-20040082562-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H (US) | 2004-04-29 | — | — | US | claimed |
| US-6624184-B1 | Identification of the inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, and | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | claimed |
| EP-1127054-A1 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000026197-A9 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2000-10-26 | — | — | WO | claimed |
| WO-2000026197-A1 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | claimed |
| EP-2803357-B1 | Angiogenesis inhibitors | UNIV JOHNS HOPKINS (US) | 2020-11-18 | — | — | EP | disclosed |
| US-9642865-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-8980930-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | UNIV JOHNS HOPKINS (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2803357-A2 | Angiogenesis inhibitors | THE JOHNS-HOPKINS UNIVERSITY (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| WO-2006017896-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006004795-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6624184-B1 | Identification of the inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, and | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885IMPDH1 2706/4885AAK1 793/4885 |
| US-20040082562-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 2009/4885 |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 2882/4885 |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885IMPDH1 2706/4885AAK1 793/4885 |
| US-20040102497-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 2009/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885IMPDH1 1/4885AAK1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.